Clinical Trial

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-12-13; most recent amendment 2026-03-04.
Status change: Not Yet Recruiting → Recruiting 2023-01-23
Trial Details
NCT Number NCT05661201
Lead Sponsor Georgetown University
Collaborators: Immune System Key Ltd
Conditions Solid Tumor, KRAS Mutation-Related Tumors
Enrollment 24 participants
Start Date 2023-04-12
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-06